Our results suggest that enhancing RORα activity in T cells under an inflammatory milieu where naïve CD4+ T cells can be differentiated into Th17 cells may be useful as a novel treatment strategy for Th17-associated diseases, such as RA. This evidence concerns the gene RORA and rheumatoid arthritis.